A peptide can show 99% HPLC purity and still be the wrong sequence. Peptide identity confirmation requires evidence beyond a purity percentage: HPLC measures the chromatographic signal assigned to a peak, whilst mass spectrometry compares observed mass with the calculated mass. Neither result alone establishes the order of every amino acid residue.
For related guidance, see our guide to interpreting peptide purity results and research peptide quality documentation reference. These explain how to keep purity, identity and batch traceability separate when reviewing laboratory records.
For an overview of NH Peptides’ stated testing process and quality documentation, see the Quality & Testing page.
Purity is a useful quality measure, but it answers a different question from identity. A high main-peak percentage does not rule out a related compound with similar chromatographic behaviour. Intact-mass analysis supports a total-mass assignment, not the order of the amino acids.
This article explains how HPLC and mass spectrometry contribute to peptide assessment, what peptide mapping adds, and how observed m/z values relate to charge states and calculated mass. It also explains the limits of each method, so laboratory documentation can be interpreted in context rather than reduced to a single purity figure.
Key Takeaways
- Assess purity and identity as separate properties; a dominant HPLC peak does not establish the peptide sequence.
- Interpret observed m/z values alongside charge states and calculated mass to assess whether mass-spectrometry data support the expected peptide.
- Use peptide mapping and sequence-informative fragment data to add evidence about amino acid order.
- Read HPLC and mass-spectrometry results together, recognising what each method measures and where its limits lie.
- Review the analytical methods and batch details documented for the sample when interpreting a certificate of analysis.
Can a peptide have high purity but wrong identity?
Yes. A high purity result does not establish that a sample matches its named peptide. When interpreting research, keep this distinction in mind: reported findings do not independently verify the identity of a separately supplied sample. Analytical identity evidence and study findings answer different questions.
Mass spectrometry for identity testing
Mass spectrometry measures peptide ions and compares their mass with the expected value for the proposed structure. In a human research paper, a clear description of the tested material helps readers assess what the findings relate to. A COA can support sample characterisation, but it cannot establish that another study used the same material. High-resolution ESI mass spectrometry typically has mass accuracy of 1-5 ppm.
Tandem mass spectrometry and sequence confirmation
Tandem mass spectrometry fragments selected ions to produce sequence-informative data. Adequate fragment coverage and interpretation can support the assigned amino acid order. A stated peptide name or reported study result is not sequence evidence. Intact-mass agreement supports total mass, while informative fragments provide evidence about residue order.
Intact mass across charge states
Electrospray ionisation can produce ions with different charge states, including doubly and triply charged ions. Each state produces a distinct m/z signal for the same intact peptide. Correctly assigning the charge relates those signals to neutral mass. To evaluate a study report, consider its analytical method and sample description rather than assuming the material’s identity.
Expected and observed molecular mass
Expected mass is calculated from a proposed structure; observed mass comes from the instrument’s spectrum. High-resolution identity matching typically requires measured mass within 5 ppm of calculated monoisotopic mass. A BPC-157 certificate example gives a molecular weight of 1419.6 Da. Human research conclusions do not replace this comparison, because an outcome cannot show whether a separate sample had the expected molecular mass.
Human research findings and analytical characterisation should therefore be read as separate evidence types. Study design and reported outcomes address the research question; mass spectrometry evaluates sample-level mass evidence. A sample can show 99% HPLC purity and still be the wrong peptide if a related compound behaves similarly during chromatography. Neither a study report nor a purity percentage alone establishes sequence identity.
How is peptide mapping used as an identity test?
Peptide mapping compares a pattern of peptide fragments with a reference to assess whether a protein or peptide has the intended structure. It adds sequence-related evidence to intact-mass results, but is not a purity measurement.
In a mapping workflow, the protein is digested into smaller peptides. Liquid chromatography separates the fragments, and mass spectrometry records molecular weights and fragment-ion data using MSe and/or MS/MS. The resulting pattern is compared with the expected reference map. Differences may indicate a substitution, modification or other structural change, depending on data coverage and interpretation.
Once a reference trace has been qualified, LC-UV analysis can serve as a routine identity test without additional mass-spectrometric detection. This requires a suitably established reference and a method that resolves the relevant peaks. Peptide mapping is not a purity test: its trace can be complex, making impurities difficult to identify. HPLC purity assessment serves a separate purpose.
A certificate of analysis (COA) should identify the methods performed for the stated lot. Check that the batch number matches the vial, then compare the testing details with the result you are interpreting. The COA should identify the testing laboratory; naming an independent laboratory provides clearer provenance than reporting a seller-only result. Read dates in relation to the lot and analysis, rather than treating them as interchangeable product identifiers.
Endotoxin testing by LAL, or Limulus amebocyte lysate, detects endotoxins. It does not establish peptide sequence or replace mass spectrometry and mapping. The COA should distinguish this result from identity and purity findings.
UK testing costs depend on the methods selected, sample preparation and whether the work includes mapping, mass spectrometry or additional assays. The test scope is the main cost driver, so there is no single price for every peptide analysis. Turnaround also depends on method complexity, preparation and laboratory workload. Consider it in relation to the specific test panel, rather than assuming it from the COA date.
The required sample amount and handling depend on the laboratory method, number of tests and whether repeat analysis is needed. Keep the sample identified by batch, sealed and protected from moisture or contamination. The laboratory’s method determines the usable quantity.
HPLC and mass spectrometry for peptide identity confirmation
HPLC and mass spectrometry assess different analytical properties of a peptide sample. Read together, their results distinguish chromatographic purity from evidence supporting molecular identity.
HPLC analysis
High-performance liquid chromatography separates sample components and estimates the share of detected signal assigned to a chromatographic peak. Reversed-phase HPLC commonly uses UV detection at 210-220 nm for peptide purity assessment. The reported percentage depends on the defined method and detected peaks; it does not independently identify the molecule. A COA recommendation is HPLC purity of at least 99%, interpreted alongside the method used.
Mass spectrometry analysis
Mass spectrometry measures ion mass-to-charge values and uses them to assess whether the sample’s measured mass agrees with the calculated peptide mass. This provides identity evidence that HPLC peak area cannot supply. A COA commonly uses mass spectrometry for identity and HPLC for purity. For most laboratory research applications, HPLC purity above 95% with positive MS identity confirmation is described as fit for use.
The results answer separate questions. HPLC indicates how much detected chromatographic signal falls within the assigned peak; mass spectrometry assesses whether measured ions support the expected molecular composition. A strong result from one method cannot substitute for the other. Even a research peptide with a dominant peak requires mass evidence to support its assigned identity.
Method details affect interpretation. HPLC purity depends on the separation conditions and detection method, so percentages from different methods are not automatically equivalent. The COA should identify the methods performed for that lot. Read the purity result alongside the chromatogram or method description, where available, rather than treating the percentage as a complete structural assessment.
Mass spectrometry can also be coupled with chromatography. Reversed-phase and size-exclusion chromatography mass spectrometry can run online without first collecting fractions. This links chromatographic separation with mass information from the eluting components. It can help show which signals correspond to separated material, although interpretation still depends on the method and data analysis.
For a practical comparison, identify the HPLC result and its method, then find the mass-spectrometry identity result. Check that both refer to the same sample and lot. Consider whether each method supports its distinct purpose: chromatographic signal for purity, measured mass for identity. Reading the results together gives a more informative assessment than either alone.

Interpreting observed m/z values
The observed m/z value is an ion’s mass-to-charge ratio, not the peptide’s neutral molecular mass. Electrospray ionisation can produce the same peptide at charge states such as +2 and +3, so each state appears at a different m/z. Correct interpretation depends on assigning the charge before comparing the result with the expected mass.
For electrospray mass spectrometry, neutral mass can be calculated from an observed ion using: M = z(m/z − 1.0073 Da). Here, M is neutral mass, z is charge state, and 1.0073 Da is the proton mass. The calculation converts a charged signal into a neutral-mass estimate. A spectrum containing multiple assigned charge states should produce consistent neutral-mass values for the same peptide.
Read the spectrum in sequence:
- Identify the reported m/z peak and its assigned charge state.
- Apply the charge correction to calculate neutral mass.
- Compare the result with the calculated monoisotopic mass for the proposed sequence.
- Review the mass error and whether other charge states support the same assignment.
This comparison depends on correct peak assignment. An isotope envelope contains peaks separated by 1 Da; confusing isotope peaks with separate charge states can distort the inferred mass. For example, an unexplained signal should not be treated as a second peptide until its isotope pattern and charge assignment have been assessed. The report should show observed m/z values, charge states, calculated neutral mass and mass error.
Instrument type also affects interpretation. MALDI-TOF mass spectrometry typically has mass accuracy of 10-50 ppm, whereas electrospray spectra commonly display multiple charge states. The method used therefore matters when comparing an observed value with a theoretical mass. Chromatography may separate components before detection, but a chromatographic peak alone does not assign an m/z signal to a sequence.
Supplier documentation should identify the analytical method and explain how observed values relate to calculated mass. A single m/z value without charge information or a stated mass assignment is difficult to assess. Agreement across assigned charge states supports the proposed intact mass, but does not establish amino acid order; sequence evidence requires informative fragments.
These measurements are analytical findings for Research use only. Not for human or veterinary use. They do not establish a medical property, suitability for consumption or a basis for medical advice. Interpret m/z data as part of the sample’s documented analytical record, not as evidence of a clinical outcome.
What methods are used to confirm peptide identity?
Identity assessment combines methods that examine different structural features. Intact molecular weight supports a total-mass assignment, while peptide mapping and fragment-ion data can provide sequence-related evidence. Amino acid analysis adds compositional information but cannot confirm residue order. The appropriate interpretation depends on the molecule and the question being tested.
Intact-mass analysis compares the measured mass with the theoretical value for the proposed structure. Agreement supports the expected total mass, but cannot distinguish sequences that share the same amino acid composition and mass. It is evidence for identity, not a complete sequence determination. For stronger characterisation, consider the mass result alongside peptide mapping and tandem mass spectrometry.
Peptide mapping analyses fragments produced by proteolytic digestion. Liquid chromatography separates the released peptides, while mass spectrometry records their molecular weights and fragment-ion data. The resulting pattern is compared with a reference map. Differences may indicate a sequence change or modification, provided the relevant regions are represented and the data are adequately interpreted.
Once a peptide-mapping reference trace has been qualified, LC-UV analysis can serve as a routine identity test without additional mass-spectrometric detection. This approach relies on the established reference and a method that distinguishes the relevant peaks. Mapping is not a substitute for purity testing: its complex trace can make impurities difficult to identify. The methods answer different analytical questions.
Amino acid analysis measures the composition of amino acids in a sample. It can support a proposed composition but cannot establish residue order. For example, samples with the same amino acid types in a different sequence may produce similar composition results. Use sequence-sensitive methods when residue order is central to the identity assignment.
For biopharmaceutical identity characterisation, intact molecular weight analysis and peptide mapping can assess the main component. Glycoproteins may also require analysis of released oligosaccharides, because attached carbohydrate structures form part of their characterisation. These methods provide complementary, not interchangeable, evidence.
Interpret the method set against the material being characterised:
- Use intact-mass analysis to assess total molecular mass.
- Use mapping and fragment-ion data to examine sequence-related features.
- Use amino acid analysis for composition, not residue order.
- Include released oligosaccharide analysis when characterising glycoproteins.
A defensible identity assignment rests on agreement between suitable methods and the proposed structure. No single result answers every question about composition, sequence and modification.
NH Peptides: Research peptides
Research peptide product claims should be checked against appropriate documentation before laboratory use. These materials are not for human use, consumption, medical diagnosis or therapeutic treatment.
For research planning, assess identity data and purity results separately. Biohacker feedback, including the feedback shared by biohackers, consists of personal accounts. Such accounts are anecdotal, not analytical evidence, and cannot establish identity, purity or laboratory performance.
Biohacker feedback may describe reported experiences, but it does not verify a research sample or its analytical characteristics. It is not evidence of suitability for human use. Explore NH Peptides’ research peptide range for laboratory studies.
Define the evidence your study requires
Set identity criteria before selecting material for a laboratory study. The analytical purpose determines whether composition, intact mass or sequence-level evidence is relevant. This makes peptide identity confirmation part of research planning, rather than a judgement based on one isolated result.
NH Peptides supplies research peptides, including Retatrutide and Tesamorlin, for laboratory studies. These materials are not for human use, consumption, medical diagnosis or therapeutic treatment. Biohacker feedback describes personal accounts and should not be treated as analytical evidence or as proof of identity, purity or laboratory performance.
Align the material under consideration with the study’s research scope and the documentation needed to assess it. For product information relevant to laboratory research, contact NH Peptides about peptide identity. A clearly defined analytical purpose gives the next research decision a sound basis.
Frequently Asked Questions
Is mass spectrometry always included in a COA?
No. A certificate should report only the analytical methods performed for the identified lot, so do not assume mass spectrometry was used unless it is listed. Check the method names and results rather than relying on a general statement that a product is tested. Compare the certificate’s lot identifier with the vial as well. A mismatch means the document may not describe the sample being assessed.
What is a peptide COA?
A peptide certificate of analysis (COA) records tests and results associated with a defined sample or batch. It can document the analytical methods used, purity findings and identity evidence, where those tests were performed. Treat it as a lot-specific analytical record, not a general product description. A certificate for one batch, for example, does not establish the results for another. Use the NH Peptides COA lookup to review published batch documents, and read the quality and testing overview for guidance on interpreting the scope of each report.
How does mass spectrometry confirm peptide identity?
Mass spectrometry measures ions from a sample and compares their mass data with values expected for the proposed peptide. A consistent match supports the proposed molecular mass. The assessment is stronger when the report gives charge states, observed m/z values and mass error. Intact-mass agreement cannot distinguish every sequence arrangement, so it is not complete proof of amino acid order.
How is peptide identity confirmed using HPLC or UPLC?
HPLC or UPLC separates sample components and produces a chromatographic profile. A retention-time match against a suitable reference, using the same method, can support an identity assignment. Similar compounds may behave similarly during separation, however, so a matching peak alone is not conclusive. Interpret the profile alongside an orthogonal method, such as mass spectrometry, and check that reference and sample were analysed under comparable conditions.
What is peptide sequence confirmation by tandem mass spectrometry?
Tandem mass spectrometry selects a peptide ion, fragments it and measures the resulting ions. The fragment pattern can be compared with sequence-predicted fragments to assess residue order. Its value depends on whether informative fragments cover the relevant sequence and can be assigned reliably. A sparse or ambiguous pattern may support only part of the proposed sequence, rather than confirming every residue.
What purity and identity data should a peptide certificate of analysis include?
Look for a batch identifier, the analytical methods performed, a reported purity result and identity evidence linked to that batch. For mass spectrometry, useful fields include observed m/z values, assigned charge states, calculated mass and mass error. A chromatogram or method description helps put the purity percentage in context. The stated sample strength should also correspond to the vial documented.
How to interpret peptide mass, charge states and mass accuracy?
First distinguish m/z from neutral molecular mass: m/z depends on both ion mass and charge. Confirm the charge assignment before comparing a signal with a calculated mass. Then consider the instrument’s stated accuracy and the method used; there is no universal tolerance for every result. Isotope peaks and separate charge states are different spectral features, so check how the report labels them.
What are the differences between peptide identity confirmation and purity testing?
Identity testing assesses whether analytical evidence supports the proposed molecule or sequence. Purity testing estimates the proportion of detected chromatographic signal assigned to the target peak under a specified method. These findings address different properties. A sample may show a dominant peak without proving its sequence, while a mass match does not quantify all impurities. Interpret both in light of the methods documented for that sample.


Pingback: Peptide Research Reference Guide | NH Peptides
Pingback: Lyophilized Peptide Reconstitution & Storage | NH Peptides
Pingback: Peptides: Retatrutide, MOTS-C, GHK-Cu & NAD+
Pingback: Peptide Mass Spectrometry Results | NH Peptides
Pingback: Peptide lot traceability: How to check COAs and lot records
Pingback: Research Peptides | NH Peptides
Pingback: UK Research Peptides: Supplier & COA Guide | NH Peptides
Pingback: Lyophilised Peptide Compounds: Stability, Reconstitution and COA Checks